因免疫治疗效果不佳而手术切除复发性纵隔脂肪肉瘤1例

IF 2.4 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Future Science OA Pub Date : 2023-10-30 DOI:10.2144/fsoa-2023-0099

Ming-Ji Wang, Shu-Quan Xu, Lei-Lei Wu, Zhi-Xin Li, Dong Xie

{"title":"因免疫治疗效果不佳而手术切除复发性纵隔脂肪肉瘤1例","authors":"Ming-Ji Wang, Shu-Quan Xu, Lei-Lei Wu, Zhi-Xin Li, Dong Xie","doi":"10.2144/fsoa-2023-0099","DOIUrl":null,"url":null,"abstract":"The feasibility of surgery after immunotherapy for mediastinal liposarcoma remains uncertain. Besides, the case of immunotherapy for liposarcoma is still lacking. We report a case of recurrence after resection of a left mediastinal liposarcoma. After recurrence, one course of pembrolizumab plus anlotinib hydrochloride showed no tumor shrinkage, and genetic testing showed CDK4 amplification and PD-L1 TPS <1%; therefore, the plan was changed to one course of pembrolizumab plus palbociclib, but the tumor still did not shrink. Thus, second tumor resection was performed. In addition, the postoperative pathology was still well-differentiated liposarcoma. The significance of immunotherapy in liposarcoma still needs to be further explored. In the absence of surgical contraindications, secondary surgery might be feasible.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Surgical resection due to poor outcome of the immunotherapy of a relapsed mediastinal liposarcoma: a case report\",\"authors\":\"Ming-Ji Wang, Shu-Quan Xu, Lei-Lei Wu, Zhi-Xin Li, Dong Xie\",\"doi\":\"10.2144/fsoa-2023-0099\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The feasibility of surgery after immunotherapy for mediastinal liposarcoma remains uncertain. Besides, the case of immunotherapy for liposarcoma is still lacking. We report a case of recurrence after resection of a left mediastinal liposarcoma. After recurrence, one course of pembrolizumab plus anlotinib hydrochloride showed no tumor shrinkage, and genetic testing showed CDK4 amplification and PD-L1 TPS <1%; therefore, the plan was changed to one course of pembrolizumab plus palbociclib, but the tumor still did not shrink. Thus, second tumor resection was performed. In addition, the postoperative pathology was still well-differentiated liposarcoma. The significance of immunotherapy in liposarcoma still needs to be further explored. In the absence of surgical contraindications, secondary surgery might be feasible.\",\"PeriodicalId\":12568,\"journal\":{\"name\":\"Future Science OA\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2023-10-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Science OA\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2144/fsoa-2023-0099\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Science OA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2144/fsoa-2023-0099","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

纵隔脂肪肉瘤免疫治疗后手术的可行性仍不确定。此外，脂肪肉瘤的免疫治疗案例仍然缺乏。我们报告一个左纵隔脂肪肉瘤切除后复发的病例。复发后，派姆单抗联合盐酸安洛替尼1个疗程未见肿瘤缩小，基因检测显示CDK4扩增，PD-L1 TPS <1%;因此，计划改为派姆单抗加帕博西尼一个疗程，但肿瘤仍然没有缩小。因此，进行第二次肿瘤切除术。术后病理仍为高分化脂肪肉瘤。免疫治疗在脂肪肉瘤中的意义还有待进一步探讨。在没有手术禁忌的情况下，二次手术可能是可行的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Surgical resection due to poor outcome of the immunotherapy of a relapsed mediastinal liposarcoma: a case report

The feasibility of surgery after immunotherapy for mediastinal liposarcoma remains uncertain. Besides, the case of immunotherapy for liposarcoma is still lacking. We report a case of recurrence after resection of a left mediastinal liposarcoma. After recurrence, one course of pembrolizumab plus anlotinib hydrochloride showed no tumor shrinkage, and genetic testing showed CDK4 amplification and PD-L1 TPS <1%; therefore, the plan was changed to one course of pembrolizumab plus palbociclib, but the tumor still did not shrink. Thus, second tumor resection was performed. In addition, the postoperative pathology was still well-differentiated liposarcoma. The significance of immunotherapy in liposarcoma still needs to be further explored. In the absence of surgical contraindications, secondary surgery might be feasible.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Science OA MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

5.00

自引率

4.00%

发文量

审稿时长

13 weeks

期刊介绍： Future Science OA is an online, open access, peer-reviewed title from the Future Science Group. The journal covers research and discussion related to advances in biotechnology, medicine and health. The journal embraces the importance of publishing all good-quality research with the potential to further the progress of research in these fields. All original research articles will be considered that are within the journal''s scope, and have been conducted with scientific rigour and research integrity. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis. Submissions of the following article types will be considered: -Research articles -Preliminary communications -Short communications -Methodologies -Trial design articles -Trial results (including early-phase and negative studies) -Reviews -Perspectives -Commentaries